BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34549489)

  • 1. Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial.
    Hwang CK; Chew EY; Cukras CA; Keenan TDL; Wong WT; Linehan WM; Chittiboina P; Pacak K; Wiley HE
    Clin Exp Ophthalmol; 2021 Dec; 49(9):1048-1059. PubMed ID: 34549489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.
    Wong WT; Liang KJ; Hammel K; Coleman HR; Chew EY
    Ophthalmology; 2008 Nov; 115(11):1957-64. PubMed ID: 18789534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Jaffe GJ; Eliott D; Wells JA; Prenner JL; Papp A; Patel S
    Ophthalmology; 2016 Jan; 123(1):78-85. PubMed ID: 26499921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
    Jaffe GJ; Ciulla TA; Ciardella AP; Devin F; Dugel PU; Eandi CM; Masonson H; Monés J; Pearlman JA; Quaranta-El Maftouhi M; Ricci F; Westby K; Patel SC
    Ophthalmology; 2017 Feb; 124(2):224-234. PubMed ID: 28029445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
    Dahr SS; Cusick M; Rodriguez-Coleman H; Srivastava SK; Thompson DJ; Linehan WM; Ferris FL; Chew EY
    Retina; 2007 Feb; 27(2):150-8. PubMed ID: 17290195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravitreal dexamethasone on macular edema in von Hippel-Lindau disease assessed using swept-source optical coherence tomography: a case report.
    Minnella AM; Pagliei V; Maceroni M; Federici M; Gambini G; Caporossi A
    J Med Case Rep; 2018 Sep; 12(1):248. PubMed ID: 30185211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease].
    Michels S; Messmer E; Sutter F; Kurz-Levin MM
    Klin Monbl Augenheilkd; 2008 Apr; 225(4):292-4. PubMed ID: 18401796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.